menu
    • menu
    [{"orgOrder":0,"company":"Palladio Zannini Industrie","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Zannini Industrie","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Palladio Zannini Industrie \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Zannini Industrie \/ Samsara BioCapital"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ General Atlantic"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.33000000000000002,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lixivaptan

    Menu

    Lixivaptan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autoso...

                            Details : Decision is based on reassessment of commercial potential of VPA-985 (lixivaptan) as potential best-in-class therapy for patients with ADPKD, following recent observation of alanine aminotransferase and aspartate aminotransferase elevations in ALERT Stud...

                            Brand Name : VPA-985

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Doses First Subject in a Global Phase 3 ACTION Study of Lixivaptan in Autosomal Domin...

                            Details : The start of dosing in the ACTION Study, designed to serve as a single registration trial and will evaluate the efficacy and safety of VPA-985 (lixivaptan), a nonpeptide selective vasopressin V2 receptor antagonist, in a broad group of ADPKD patients.

                            Brand Name : VPA-985

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 24, 2022

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $330.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Centessa Announces Pricing of Initial Public Offering

                            Details : Lixivaptan (VPA-985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.

                            Brand Name : VPA-985

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 27, 2021

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $330.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : General Atlantic

                            Deal Size : $250.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutica...

                            Details : Centessa Pharmaceuticals portfolio consists of four clinical stage programs, including two that are in late-stage clinical development. Palladio Biosciences, a subsidiary of Centessa, is developing lixivaptan, an oral non-peptide of kidney diseases.

                            Brand Name : VPA-985

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2021

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : General Atlantic

                            Deal Size : $250.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Palladio Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Palladio Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Centessa Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Palladio Biosciences Doses First Patient With Lixivaptan in The ALERT Study

                            Details : The ALERT Study, designed to assess the safety of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD) patients who previously discontinued therapy with tolvaptan due to liver toxicity, is currently recruiting patients in the United States.

                            Brand Name : VPA-985

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2020

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Centessa Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Palladio Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Palladio Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Centessa Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Pre...

                            Details : The presentation will include the results of more than 12 months of safe treatment with lixivaptan in this study, which was conducted as an expanded access clinical study under an IND.

                            Brand Name : VPA-985

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 20, 2020

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Centessa Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Palladio Zannini Industrie

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Palladio Zannini Industrie

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Samsara BioCapital

                            Deal Size : $20.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Palladio Completes $20 Million Series B Financing

                            Details : Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations.

                            Brand Name : VPA-985

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 25, 2020

                            Lead Product(s) : Lixivaptan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Samsara BioCapital

                            Deal Size : $20.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth